Correction to: Treatment Persistence in Patients Cycling on Subcutaneous Tumor Necrosis Factor-Alpha Inhibitors in Inflammatory Arthritis: A Retrospective Study

被引：0
|
作者：
Johan Dalén
Amy Puenpatom
Karin Luttropp
Axel Svedbom
Christopher M. Black
机构：
[1] ICON Plc,
[2] Center for Observational and Real-World Evidence,undefined
[3] Merck & Co.,undefined
[4] Inc,undefined
[5] Center for Observational and Real-World Evidence (CORE),undefined
[6] Merck & Co.,undefined
[7] Inc.,undefined
来源：
Advances in Therapy | 2022年 / 39卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：256 / 256
相关论文
共 50 条
  • [1] TREATMENT PERSISTENCE IN PATIENTS CYCLING ON SUBCUTANEOUS TUMOR NECROSIS FACTOR-ALPHA INHIBITORS IN INFLAMMATORY ARTHRITIS - A RETROSPECTIVE STUDY
    Dalen, J.
    Puenpatom, A.
    Luttropp, K.
    Black, C.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 851 - 852
  • [2] Treatment Persistence in Patients Cycling on Subcutaneous Tumor Necrosis Factor-Alpha Inhibitors in Inflammatory Arthritis: A Retrospective Study
    Dalen, Johan
    Puenpatom, Amy
    Luttropp, Karin
    Svedbom, Axel
    Black, Christopher M.
    [J]. ADVANCES IN THERAPY, 2022, 39 (01) : 244 - 255
  • [3] Treatment Persistence in Patients Cycling on Subcutaneous Tumor Necrosis Factor-Alpha Inhibitors in Inflammatory Arthritis: A Retrospective Study
    Johan Dalén
    Amy Puenpatom
    Karin Luttropp
    Axel Svedbom
    Christopher M. Black
    [J]. Advances in Therapy, 2022, 39 : 244 - 255
  • [4] Cost of Non-Persistence in the Treatment with Subcutaneous Tumor Necrosis Factor-Alpha Inhibitors of Inflammatory Arthritis: A Propensity Score Matching Approach
    Dalen, Johan
    Luttropp, Karin
    Olofsson, Tor
    Black, Christopher
    Puenpatom, Amy
    [J]. ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [5] The safety of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis
    Victoria Hernandez, Maria
    Sanmarti, Raimon
    Canete, Juan D.
    [J]. EXPERT OPINION ON DRUG SAFETY, 2016, 15 (05) : 613 - 624
  • [6] Characterization of the treatment of rheumatoid arthritis for patients prescribed tumor necrosis factor-alpha inhibitors
    Stockl, K
    Jarrar, M
    Tandon, N
    [J]. VALUE IN HEALTH, 2004, 7 (03) : 245 - 245
  • [7] Lessons learned in the use of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis
    Ted R. Mikuls
    Arthur L. Weaver
    [J]. Current Rheumatology Reports, 2003, 5 (4) : 270 - 277
  • [8] TUMOR NECROSIS FACTOR INHIBITORS PERSISTENCE IN PSORIATIC ARTHRITIS PATIENTS
    Vieira-Sousa, E.
    Eusebio, M.
    Avila-Ribeiro, P.
    Khmelinskii, N.
    Machado, A. R.
    Martins-Rocha, T.
    Bernardes, M.
    Santos-Faria, D.
    Leite Silva, J.
    Santos, H.
    Miguel, C.
    Carvalho, P.
    Costa, T.
    Teixeira, L.
    Meirinhos, T.
    Nero, P.
    Santos, M. J.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2018, 36 (04) : 731 - 732
  • [9] Inhibitors of tumour necrosis factor-alpha for the treatment of arthritis and uveitis in childhood
    Heiligenhaus, A.
    Horneff, G.
    Greiner, K.
    Mackensen, F.
    Zierhut, M.
    Foeldvari, I.
    Michels, H.
    [J]. KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE, 2007, 224 (06) : 526 - 531
  • [10] Reduction of haemostatic and inflammatory biomarkers by tumor necrosis factor-alpha blockade in patients with rheumatoid arthritis
    Ingegnoli, F.
    Cugno, M.
    Favalli, E.
    Soldi, A.
    Griffini, S.
    Bonanni, E.
    Fantini, F.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : A56 - A56
12345